| Major |
Rifampin+pyrazinamide |
9 (17.0%) |
Combination may cause liver damage |
|
Rifampin+isoniazid |
9 (17.0%) |
Combination may cause liver damage |
|
Cotrimoxazole+leucovorin |
8 (15.0%) |
Combination may increase risk of treatment failure |
|
Phenytoin+artemether |
5 (9.4%) |
Phenytoin may significantly reduce the blood levels of artemether |
|
Warfarin+heparin |
4 (7.5%) |
Combination can cause bleeding more easily |
|
Ceftriaxone+leucovorin |
4 (7.5%) |
May cause precipitation of ceftriaxone-calcium salt |
| Moderate |
Ceftriaxone+furosemide |
12 (4.7%) |
Furosemide increase the risk of kidney damage by cephalosporin |
|
Sulfadiazine+pyrimethamine |
10 (3.9%) |
Combination may increase the risk of anemia |
|
Isoniazid+ethambutol |
9 (3.5%) |
Combination may increase the risk of nerve damage |
|
Cotrimoxazole+pyrimethamine |
8 (3.2%) |
Combination may increase the risk of anemia |
|
Metronidazole+phenytoin |
6 (2.4%) |
Combination may increase phenytoin level |
|
Leucovorin+phenytoin |
6 (2.4%) |
Leucovorine can decrease the bood level and effects of phenytoin |
|
Sulfadiazine+phenytoin |
6 (2.4%) |
Sulfodiazine increase the effect of phenytoin |
| Minor |
Ceftriaxone+phenytoin |
9 (8.4%) |
Ceftriaxone may displace phenytoin from serum protein bleeding site |
|
Ceftriaxone+heparin |
7 (6.5%) |
Combination can increase risk of bleeding |
|
Furosemide+aspirins |
6 (5.6%) |
Salicylates in anti-inflammatory dosage may blunt the diuretic and natriuretic response to loop diuretics |
|
Furosemide+doxycycline |
5 (4.7%) |
Combination may decrease renal function manifested by increase in clotting factor |
|
Digoxin+spironolactone |
4 (3.7%) |
Spironolactone may reduce tubular secretion of digoxin |
|
Warfarin+furosemide |
4 (3.7%) |
Furosemide may displace warfarin from plasma protein binding site |
|
Warfarin+spironolactone |
4 (3.7%) |
Spironolactone may cause dieresis and hemo concentration of clotting factor |
|
SMX+phenytoin |
4 (3.7%) |
SMX may displace phenytoin from serum protein binding site |
